On September 23, government enforcement partner Joshua Levy and government enforcement associate Sean Seelinger authored an article in Law360. The authors discuss the post-settlement compliance terms and ongoing oversight to which pharmaceutical companies are subject even after they settle DOJ investigations, and explore the impact of this trend on the life sciences industry.
